Key result
The reduction-duration-homogeneity index is proposed as a novel three-component vector index to evaluate and compare blood pressure coverage offered by antihypertensive drugs over 24 hours.
The RDH index is proposed as a novel three-component vector index to evaluate and compare blood pressure coverage offered by antihypertensive drugs over 24 hours.
RDH index may refine 24-hour BP coverage assessment; hypothesis-generating and requires validation before clinical adoption.
We propose a new vector index for the statistical assessment of antihypertensive treatment duration and homogeneity from ambulatory blood pressure monitoring. We termed this approach for evaluating and comparing blood pressure coverage offered by antihypertensive drugs over 24 h as the reduction-duration-homogeneity index. The reduction-duration-homogeneity index is a three-component vector index that incorporates information about the reduction, duration, and homogeneity of antihypertensive treatment, as well as their statistical significance. The advantages of the reduction-duration-homogeneity index are demonstrated by several comparative examples.
No takes yet. Share an insight, caveat, or question.
Aboy et al. (2006) studied Hypertension. Reduction-duration-homogeneity (RDH) index was evaluated on Statistical assessment of antihypertensive treatment reduction, duration, and homogeneity. The reduction-duration-homogeneity index is proposed as a novel three-component vector index to evaluate and compare blood pressure coverage offered by antihypertensive drugs over 24 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: